You might also like
Inari Medical, Inc. (NARI) is a medical device company specializing in innovative, minimally invasive solutions for venous and vascular diseases. The company develops and commercializes catheter-based mechanical thrombectomy devices and accessories designed to treat conditions such as venous thromboembolism (VTE), chronic venous disease, and critical limb-threatening ischemia (CLTI). NARI's mission is to improve patient outcomes by establishing its treatments as the standard of care in these underserved medical areas.
- Venous Thromboembolism (VTE) - Provides solutions for treating deep vein thrombosis (DVT) and pulmonary embolism (PE) using catheter-based mechanical thrombectomy devices like the FlowTriever and ClotTriever systems.
- Emerging Therapies - Addresses chronic venous disease, critical limb-threatening ischemia (CLTI), acute limb ischemia (ALI), dialysis access management, and arterial thromboembolism with innovative devices such as the LimFlow System and VenaCore.
- Given the GAAP operating loss of $13.6 million in Q3 2024 compared to a GAAP operating income of $2.1 million in the prior year, can you detail the specific initiatives that will drive you to sustained GAAP operating profitability in the first half of 2025, and what obstacles might impede this goal?
- With R&D expenses increasing significantly due to a one-time non-cash impairment charge and other factors, how do you plan to reduce R&D expenses as a percentage of revenue without hindering innovation and product development that are crucial for maintaining your competitive edge?
- Considering the current consensus projects 18% growth for 2025, but you aspire to be a 20% grower, what concrete strategies are in place to bridge this gap, and what risks could prevent you from achieving the higher growth rate?
- As you anticipate positive results from the PEERLESS trial, is there a concern that this could create a class effect benefiting other companies in the mechanical thrombectomy space, and how will you ensure that Inari captures the majority of the potential market expansion?
- Despite international revenue growing by 76.4%, it remains a small fraction of total revenue; what are the primary challenges in scaling international sales to reach your goal of it accounting for at least 20% of Inari's revenue, and what strategies are you implementing to overcome these hurdles?